Ethyl 5-bromoimidazo[1,5-a]pyridine-1-carboxylate, 98%, 1g

4-Bromo-2-methyl-2,7-naphthyridin-1(2H)-one, 97%, 250mg

Bromfenac (sodium), 50mg

6-bromo-5-methyl-1H,2H,3H-imidazo[4,5-b]pyridine-2-thione, 97%, 250mg

GC-Kapillarsäule ROTI®Cap-5, unpolar, L 15 m, Ø-Innen 0,32 mm, Filmd. 1,00 µm, 1 Stück

(S)-4,4-dimethyl-5-oxopyrrolidine-2-carboxylic acid, 98%, 1g

[S(R)]-N-[(R)-[6-(Diphenylphosphino)benzo[d][1,3]dioxol-5-yl]-1-naphthalenylmethyl]-2-methyl-2-propanesulfinamide, 95%, 100mg

(1R,2S)-Cyclobutane-1,2-dicarboxylic acid, 97.0%, 10g

1,2,3,4-Tetrahydroisoquinolin-8-ol, 95.0%, 1g

5-Methyl-nicotinic acid, 97.0%, 1g

4-(3,4,5-trimethoxybenzoyl)-1-oxa-4-azaspiro[4.5]decane-3-carboxylic acid, 95.0%, 1g

3-Ethyl-1,1,2-trimethyl-1H-benzo[e]indol-3-ium Iodide>98.0%(HPLC)(T)25g

Poly(sodium 4-styrenesulfonate), average Mw ~70,000, 100g